AOBiome Therapeutics, which is developing several intranasal ammonia oxidizing bacteria (AOB) candidates, said that Judith Ng-Cashin was appointed Chief Medical Officer as of October 1, 2018. Ng-Cashin was most recently Chief Scientific Officer at Syneos Health. She has also held a variety of executive positions at IQVIA (formerly Quintiles) and GSK.
In April 2018, AOBiome announced initiation of a Phase 2 trial of its AOB nasal spray for the prevention of episodic migraine. The company is also developing intranasal AOB formulations for the treatment of allergic rhinitis and for hypertension.
AOBiome President and CEO Todd Krueger said, “Dr. Ng Cashin has extensive background in both infectious disease and dermatology and will be invaluable as we advance microbial-based drugs through clinical development. She brings a wealth of experience to the team in both early and late stage drug development with major pharmaceutical companies where she managed clinical research, interacted with the FDA, and developed clinical and portfolio strategies. We look forward to the insight and depth of knowledge Judi brings to AOBiome.”
Ng-Cashin commented, “Joining the AOBiome team is an exciting opportunity to advance the application of ammonia oxidizing bacteria to the treatment of human disease. Reestablishing the symbiotic relationship between bacteria and human to restore important biologic and biochemical processes is a growing area in science and medicine. At AOBiome, we have the potential to bring a first-in-class live biotherapeutic to patients. With my experience in microbiology, infectious diseases, dermatology, and drug development, I believe I can help lead the company toward this goal.”
Read the AOBiome press release.
